Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Gender-Affirming Hormone Therapy and Thrombosis – RPTH Journal
Mette Bøgehave/LinkedIn
Aug 6, 2026, 05:53

Gender-Affirming Hormone Therapy and Thrombosis – RPTH Journal

RPTH Journal shared a post on LinkedIn about a recent article by Mette Bøgehave et al, adding:

“Gender-affirming hormone therapy and thrombosis: What happens to the fibrin clot?

Gender-affirming hormone therapy (GAHT) is known to influence thrombotic risk, but the underlying mechanisms, particularly the effects on fibrin clot properties, have remained unclear.

A new prospective cohort study in RPTH Journal addresses this directly, following 251 transgender women and 320 transgender men over 12 months.

Feminizing GAHT:

  • Increased clot formation velocity, maximum absorbance, and overall haemostasis potential
  • Reduced clot lysis
  • Oral estradiol was associated with the largest changes, suggesting route of administration matters

Masculinizing GAHT:

  • Decreased clot formation parameters and fibre diameter
  • Increased clot lysis and fibre density

This cohort provides some of the clearest mechanistic evidence to date linking GAHT to thrombotic risk,and highlights the importance of route of administration, particularly for feminizing therapy.”

Title: Feminizing and masculinizing gender-affirming hormone therapy affects fibrin clot characteristics in opposite directions

Authors: Mette Bøgehave, Dorte Glintborg, Louise Lehmann Christensen, Guy T’Sjoen, Martin den Heijer, Marianne Skovsager Andersen, Else-Marie Bladbjerg

Gender-Affirming Hormone Therapy and Thrombosis - RPTH Journal

Stay updated on all scientific advances with Hemostasis Today.

 

 

Dorte Glintborg Else-Marie Bladbjerg Guy T'Sjoen Louise Lehmann Christensen Marianne Skovsager Andersen Martin den Heijer Mette Bøgehave
NewsFeed